Veterinary Drug Prices Are 300-800% Higher Than Identical Human Drugs

Many medications prescribed for pets are chemically identical to human drugs — the same molecule, the same dose, the same manufacturer — but sold at dramatically higher prices when dispensed through a veterinary pharmacy. Fluoxetine (Prozac) for a medium-sized dog costs $45-80/month at a vet clinic; the identical generic human formulation costs $4-10/month at Costco or Walmart. Gabapentin for pain management costs $60-90/month from a vet; $8-15/month from a human pharmacy. Omeprazole (Prilosec) for acid reflux: $40-70/month veterinary vs. $8-12/month over the counter for humans. The markup ranges from 300% to 800% depending on the drug. Pet owners are often unaware they have the option to fill prescriptions at a human pharmacy. Veterinarians are legally required to provide a written prescription upon request (per FTC guidance and many state laws), but many clinics do not proactively offer this. Some actively discourage it by claiming the human formulation is 'different' or 'not safe for pets' — which, for many drugs, is flatly untrue. The clinic has a financial incentive to dispense in-house: drug sales represent 15-25% of a typical veterinary practice's revenue, and the markup on dispensed medications is one of the highest-margin line items in the business. This hits hardest for chronic conditions. A dog with epilepsy, hypothyroidism, or arthritis may need daily medication for 8-12 years. The cumulative difference between veterinary pricing and human pharmacy pricing over the animal's lifetime can exceed $5,000-$10,000 per condition. For pet owners already stretching to afford regular vet visits, this ongoing drug cost becomes the breaking point that leads to medication non-compliance, undertreated disease, and ultimately worse outcomes for the animal. The structural reason this persists is that there is no pharmacy benefit manager (PBM) equivalent in veterinary medicine, no drug price negotiation entity, and no regulatory pressure for price transparency. Veterinary drug pricing is entirely unregulated — clinics set whatever markup the market will bear. The handful of veterinary-specific drugs (those with no human equivalent) have even less price competition, as they may be manufactured by only one or two companies. The FDA's Minor Use/Minor Species (MUMS) Act, meant to incentivize development of animal-specific drugs, actually grants extended exclusivity periods that reduce generic competition.